{"id":23335,"title":"Prospective cohort of AIDS patients screened for cryptococcal antigenaemia, pre-emptively treated and followed in Midwest Brazil","title_html":"Prospective cohort of AIDS patients screened for cryptococcal antigenaemia, pre-emptively treated and followed in Midwest Brazil","image":{"source":"https:\/\/s3.amazonaws.com\/pr-journal\/bf596hd6.jpg","placeholder":"https:\/\/s3.amazonaws.com\/pr-journal\/bf596hd6.jpg"},"doi":"dx.doi.org\/10.17504\/protocols.io.22fggbn","doi_status":2,"uri":"prospective-cohort-of-aids-patients-screened-for-c-22fggbn","type_id":1,"published_on":1564157162,"parent_protocols":[],"parent_collections":[],"version_id":1,"created_on":1558357260,"categories":null,"creator":{"name":"Moara Borges","affiliation":null,"affiliations":[{"affiliation":null,"url":null,"is_default":1}],"username":"moara-borges","link":"https:\/\/doi.org\/10.1371\/journal.pone.0219928","image":{"source":"\/img\/avatars\/018.png","placeholder":"\/img\/avatars\/018.png"},"badges":[{"id":2,"image":{"source":"\/img\/badges\/bronze.svg","placeholder":"\/img\/badges\/bronze.svg"},"name":"Author"}],"research_interests":null,"blocked_by_you":false,"blocked_you":false},"journal":"PLOS One","journal_name":"PLOS One","journal_link":"https:\/\/doi.org\/10.1371\/journal.pone.0219928","article_citation":"Borges MASB,  Filho JAdA,  Oliveira BdJS,  Moreira IS,  Paula VVd,  Bastos ALd,  Soares RdBA,  Turchi MD (2019) Prospective cohort of AIDS patients screened for cryptococcal antigenaemia, pre-emptively treated and followed in Brazil. PLoS ONE  14(7): e0219928. doi: <a target=\"_blank\" href=\"https:\/\/dx.doi.org\/10.1371\/journal.pone.0219928\">10.1371\/journal.pone.0219928<\/a> ","public":1,"has_versions":1,"link":"https:\/\/doi.org\/10.1371\/journal.pone.0219928","total_collections":0,"number_of_steps":16,"authors":[{"name":"Moara Borges","affiliation":"Instituto de Patologia Tropical e Sa\u00fade P\u00fablica da universidade Federal de Goi\u00e1s","affiliations":[],"username":"moara-borges","link":null,"image":{"source":"\/img\/avatars\/018.png","placeholder":"\/img\/avatars\/018.png"},"badges":[],"research_interests":null,"blocked_by_you":false,"blocked_you":false},{"name":"Jo\u00e3o Alves de Ara\u00fajo Filho","affiliation":"Instituto de Patologia Tropical e Sa\u00fade P\u00fablica da universidade Federal de Goi\u00e1s","affiliations":[],"username":null,"link":null,"image":{"source":null,"placeholder":null},"badges":[],"research_interests":null,"blocked_by_you":false,"blocked_you":false},{"name":"Mar\u00edlia Dalva Turchi","affiliation":"Instituto de Patologia Tropical e Sa\u00fade P\u00fablica da universidade Federal de Goi\u00e1s","affiliations":[],"username":null,"link":null,"image":{"source":null,"placeholder":null},"badges":[],"research_interests":null,"blocked_by_you":false,"blocked_you":false}],"versions":[],"groups":[],"has_subprotocols":0,"is_subprotocol":0,"is_bookmarked":0,"can_be_copied":1,"can_remove_fork":1,"forks_count":{"private":0,"public":0},"access":{"can_view":1,"can_remove":0,"can_add":0,"can_edit":0,"can_publish":0,"can_get_doi":0,"can_share":1,"can_move":1,"can_move_outside":1,"can_transfer":1,"can_download":1,"is_locked":0},"steps":[{"id":743777,"guid":"5879E1D928ED4427B8DADF13711CE26B","previous_id":743790,"previous_guid":"F0E48DC141C44D9C9060DBAF693974A5","modified_on":0,"protocol_id":0,"components":[{"id":1054723,"guid":"4FE5E5F61BB3428699CB989D3B407F1F","order_id":1,"type_id":6,"title":"Section","source":{"title":""}},{"id":1054724,"guid":"E4626E38D6EA439B93FC58B011262C13","order_id":1,"type_id":1,"title":"description","source":{"description":"<div class = \"text-blocks\"><div class = \"text-block\"><span style = \"font-weight:bold;\">Inclusion Criteria:<\/span><\/div><div class = \"text-block\">Laboratory confirmed diagnosis of HIV-1 infection<\/div><div class = \"text-block\">CD4<200 cells\/\u00b5L measured in the last 6 months<\/div><div class = \"text-block\">Age \u226518 years<\/div><div class = \"text-block\">With or without neurological symptoms<\/div><div class = \"text-block\">Hospitalized or outpatient<\/div><div class = \"text-block\">Regardless of antiretroviral therapy (ARV) experience or adherence<\/div><\/div>"}}],"cases":null,"data":null,"section":null,"section_color":null,"critical":null,"critical_id":null,"duration":0},{"id":743778,"guid":"46E206E6D268462DB5EB2A1444737ECB","previous_id":null,"previous_guid":null,"modified_on":0,"protocol_id":0,"components":[{"id":1054723,"guid":"E095C5A7EC374000B440C2A2860375BE","order_id":1,"type_id":6,"title":"Section","source":{"title":""}},{"id":1054724,"guid":"4BA22794908040A9B965B7FB2F70A800","order_id":1,"type_id":1,"title":"description","source":{"description":"<div class = \"text-blocks\"><div class = \"text-block\"><span style = \"font-weight:bold;\">Study Type<\/span><span>: Prospective cohort<\/span><\/div><\/div>"}}],"cases":null,"data":null,"section":null,"section_color":null,"critical":null,"critical_id":null,"duration":0},{"id":743779,"guid":"ADBFE864E4464B899D66CB6A7CC83E88","previous_id":743777,"previous_guid":"5879E1D928ED4427B8DADF13711CE26B","modified_on":0,"protocol_id":0,"components":[{"id":1054723,"guid":"E3EC1213A37949B4987FEDF5ADD4F5E2","order_id":1,"type_id":6,"title":"Section","source":{"title":""}},{"id":1054724,"guid":"D724CF53CDEF45C9A4533F9BE059DCF9","order_id":1,"type_id":1,"title":"description","source":{"description":"<div class = \"text-blocks\"><div class = \"text-block\"><span style = \"font-weight:bold;\">Exclusion Criteria:<\/span><\/div><div class = \"text-block\">Prior known history of cryptococcal disease<\/div><div class = \"text-block\">Current known pregnancy<\/div><\/div>"}}],"cases":null,"data":null,"section":null,"section_color":null,"critical":null,"critical_id":null,"duration":0},{"id":743780,"guid":"308A27A0EEBE4811829237C7C5760811","previous_id":743795,"previous_guid":"3ACC44C07B0111E9821BADCEB9CA6790","modified_on":0,"protocol_id":0,"components":[{"id":1054723,"guid":"45F4567D3AF14DF7B3E20394A2269521","order_id":1,"type_id":6,"title":"Section","source":{"title":""}},{"id":1054724,"guid":"4D2748EE85AC4E0F912FFBFA29030789","order_id":1,"type_id":1,"title":"description","source":{"description":"<div class = \"text-blocks\"><div class = \"text-block\"><span style = \"font-weight:bold;\">Recruitment<\/span><\/div><div class = \"text-block\">The recruitment of participants will be made by two strategies:<\/div><div class = \"text-block\">1)Outpatient and in patients who fulfilled inclusion criteria and have no cryptococcal disease previously diagnosed, will be enrolled.  A medical appointment will be scheduled. The structured interview will be performed by the assistant physician or a medical researcher.<\/div><\/div>"}}],"cases":null,"data":null,"section":null,"section_color":null,"critical":null,"critical_id":null,"duration":0},{"id":743781,"guid":"16E3D47D476B4BA7841EFEC31EA1362D","previous_id":743780,"previous_guid":"308A27A0EEBE4811829237C7C5760811","modified_on":0,"protocol_id":0,"components":[{"id":1054723,"guid":"286878D1F8744189872B8FB29DEBD853","order_id":1,"type_id":6,"title":"Section","source":{"title":""}},{"id":1054724,"guid":"8728112E058345EE84AE1B271E9143B0","order_id":1,"type_id":1,"title":"description","source":{"description":"<div class = \"text-blocks\"><div class = \"text-block\"><span style = \"font-weight:bold;\">Recruitment<\/span><\/div><div class = \"text-block\">2)The Central Laboratory of Public Health confidentially provide researchers with a list of patients with CD4 <200 cells\/\u00b5L assisted in the service in question.A first chart review will be performed, aiming to clarify history of cryptococcosis or death. A medical appointment will be scheduled with a medical researcher for the interview.<\/div><\/div>"}}],"cases":null,"data":null,"section":null,"section_color":null,"critical":null,"critical_id":null,"duration":0},{"id":743782,"guid":"09D8CAFDAF5C4FF3B4F7F250D97964AF","previous_id":743781,"previous_guid":"16E3D47D476B4BA7841EFEC31EA1362D","modified_on":0,"protocol_id":0,"components":[{"id":1054723,"guid":"5616D90E067744608116BAA264056731","order_id":1,"type_id":6,"title":"Section","source":{"title":""}},{"id":1054724,"guid":"B880C2683AB042B6A29AFEA11AFD354E","order_id":1,"type_id":1,"title":"description","source":{"description":"<div class = \"text-blocks\"><div class = \"text-block\"><span style = \"font-weight:bold;\">Structured Interview<\/span><\/div><div class = \"text-block\">During the scheduled visit or assistant physician evaluation, the main purpose of the study will be explained to the participant or legal reponsable. The risk of opportunistic diseases including cryptococcosis because of low cd4 count will be explained. The patients will be informed about the diagnostic test to be performed - serum CrAg using Lateral Flow Aassay (Immuno-Mycologics Inc\u00ae). <\/div><div class = \"text-block\">The structured interview is based on an adapted form from the Brazilian Cryptococcosis Network. Socio-demographic, clinical and laboratory data will be accessed.<\/div><div style = \"text-align :; float : ;\"><img style = \"\" src = \"https:\/\/s3.amazonaws.com\/pr-journal\/bgvf6hd6.jpg\" \/><\/div><div style = \"text-align :; float : ;\"><img style = \"\" src = \"https:\/\/s3.amazonaws.com\/pr-journal\/bgvg6hd6.jpg\" \/><\/div><div class = \"text-block\">Variables: age, sex, time of HIV diagnosis, CD4 cell count, HIV viral load, ART history, previous opportunistic infections and current systemic or neurological symptoms. <\/div><div class = \"text-block\">General symptoms: fever, weight loss, asthenia, pulmonary symptoms, diarrhoea <\/div><div class = \"text-block\">Neurological symptoms: headache, convulsions, changed mental state, dizziness, and visual or auditory deficit.<\/div><\/div>"}},{"id":1054725,"guid":"FE526AF0EED94A82B357C817823B39F1","order_id":2,"type_id":1,"title":"description","source":{"description":"<div style = \"text-align :; float : ;\"><img style = \"\" src = \"https:\/\/s3.amazonaws.com\/pr-journal\/bgvf6hd6.jpg\" \/><\/div>"}},{"id":1054726,"guid":"0DD6492427514EE9AE3782412DA06F54","order_id":3,"type_id":1,"title":"description","source":{"description":"<div style = \"text-align :; float : ;\"><img style = \"\" src = \"https:\/\/s3.amazonaws.com\/pr-journal\/bgvg6hd6.jpg\" \/><\/div>"}}],"cases":null,"data":null,"section":null,"section_color":null,"critical":null,"critical_id":null,"duration":0},{"id":743783,"guid":"17A255805F814C2DAF60703FB39C0B56","previous_id":743784,"previous_guid":"59C2D67FA2DB4AE1A9A9FCA4BFB7C55B","modified_on":0,"protocol_id":0,"components":[{"id":1054723,"guid":"D1ECB4C602D046BB8A0CC0EDA7D88404","order_id":1,"type_id":6,"title":"Section","source":{"title":""}},{"id":1054724,"guid":"579319BB28DB44579F01D816ED164D34","order_id":1,"type_id":1,"title":"description","source":{"description":"<div class = \"text-blocks\"><div class = \"text-block\"><span style = \"font-weight:bold;\">Management - CrAg negative<\/span><\/div><div class = \"text-block\"> The CrAg negative patients will be referred to the attending physician for follow-up and culture exams will be checked in the first 30 days. <\/div><\/div>"}}],"cases":null,"data":null,"section":null,"section_color":null,"critical":null,"critical_id":null,"duration":0},{"id":743784,"guid":"59C2D67FA2DB4AE1A9A9FCA4BFB7C55B","previous_id":743786,"previous_guid":"4B9D2443844548B287E86E6F6143D3EC","modified_on":0,"protocol_id":0,"components":[{"id":1054723,"guid":"C65315A30BFD4BECBBBD349611FFEFB0","order_id":1,"type_id":6,"title":"Section","source":{"title":""}},{"id":1054724,"guid":"B3172B9F3EE843C48C69A7AD97EE65CE","order_id":1,"type_id":1,"title":"description","source":{"description":"<div class = \"text-blocks\"><div class = \"text-block\"><span style = \"font-weight:bold;\">Laboratory exams<\/span><\/div><div class = \"text-block\">The participantswill then referred to the hospital's internal laboratory for venipuncture and laboratory tests.<\/div><div class = \"text-block\">- serum CrAg, fungal blood culture, blood count, proteinogram, urea, creatinine.<\/div><div class = \"text-block\">- cerebrospinal fluid (CSF) rotine, fungal culture, India Ink, CrAg in CSF<\/div><div class = \"text-block\">The CrAg LFA test result will be available in up to 24 hours. The local laboratory will informe the researcher when the CrAg test was positive.<\/div><\/div>"}}],"cases":null,"data":null,"section":null,"section_color":null,"critical":null,"critical_id":null,"duration":0},{"id":743785,"guid":"C7CC247181E046C2965268E5EBBF45D2","previous_id":743783,"previous_guid":"17A255805F814C2DAF60703FB39C0B56","modified_on":0,"protocol_id":0,"components":[{"id":1054723,"guid":"EFC966A54F8041C6AE4BBB58D0986582","order_id":1,"type_id":6,"title":"Section","source":{"title":""}},{"id":1054724,"guid":"57ED2FF7467549D7BF869C28255DF370","order_id":1,"type_id":1,"title":"description","source":{"description":"<div class = \"text-blocks\"><div class = \"text-block\"><span style = \"font-weight:bold;\">Management - CrAg positive<\/span><\/div><div class = \"text-block\">Patients with positive antigenemia will be called up to an appointment with the researcher or the attending physician to rule out CNS involvement. A lumbar puncture will be performed with CSF  analysed. The risks of the procedure will  be clarified.<\/div><div class = \"text-block\">CSF analysis: biochemistry, cellularity, India ink, direct research and culture for bacteria, fungi and mycobacteria and CrAg by LFA. <\/div><div class = \"text-block\">When the rachimanometer is available, the intracranial pressure will be measured <\/div><\/div>"}}],"cases":null,"data":null,"section":null,"section_color":null,"critical":null,"critical_id":null,"duration":0},{"id":743786,"guid":"4B9D2443844548B287E86E6F6143D3EC","previous_id":743782,"previous_guid":"09D8CAFDAF5C4FF3B4F7F250D97964AF","modified_on":0,"protocol_id":0,"components":[{"id":1054723,"guid":"63940E8E06134B02A104B6A3F273F2C2","order_id":1,"type_id":6,"title":"Section","source":{"title":""}},{"id":1054724,"guid":"D0366C943DF94F96B03863B3C0DC7805","order_id":1,"type_id":1,"title":"description","source":{"description":"<div class = \"text-blocks\"><div class = \"text-block\"><span style = \"font-weight:bold;\">Recruitment - Chart review<\/span><\/div><div class = \"text-block\"> Physical and electronic medical records will be accessed at the beginning of the study, objecting personal and laboratory background. <\/div><\/div>"}}],"cases":null,"data":null,"section":null,"section_color":null,"critical":null,"critical_id":null,"duration":0},{"id":743787,"guid":"6137B3EF574C4DF88959801581222ECE","previous_id":743785,"previous_guid":"C7CC247181E046C2965268E5EBBF45D2","modified_on":0,"protocol_id":0,"components":[{"id":1054723,"guid":"686F749909C14C909B870D921491EB3D","order_id":1,"type_id":6,"title":"Section","source":{"title":""}},{"id":1054724,"guid":"4D2A5EB63CD14689932896FE86D2B92A","order_id":1,"type_id":1,"title":"description","source":{"description":"<div class = \"text-blocks\"><div class = \"text-block\"><span style = \"font-weight:bold;\">Management - CrAg positive<\/span><\/div><div class = \"text-block\">During couple months after the enrollment date, all positive subjects will be reassessed in at least 2 medical consultations with the researcher: for initial orientation and prescription of preemptive treatment (WHO Guideline 2018) and for assessing adherence. <\/div><div class = \"text-block\">In the presence of cryptococcal meningitis, subjects receive treatment with amphotericin + fluconazole<\/div><\/div>"}}],"cases":null,"data":null,"section":null,"section_color":null,"critical":null,"critical_id":null,"duration":0},{"id":743788,"guid":"B7DF03C01F4E4D3296B2B458E68F2C98","previous_id":743778,"previous_guid":"46E206E6D268462DB5EB2A1444737ECB","modified_on":0,"protocol_id":0,"components":[{"id":1054723,"guid":"1BF02B0EB01F49A69FDDF9787B9E3C2D","order_id":1,"type_id":6,"title":"Section","source":{"title":""}},{"id":1054724,"guid":"ADA4C4B46FB34075AB772533F560C2E2","order_id":1,"type_id":1,"title":"description","source":{"description":"<div class = \"text-blocks\"><div class = \"text-block\"><span style = \"font-weight:bold;\">Objectives<\/span><\/div><div class = \"text-block\">Estimate the prevalence of cryptococcal antigenemia in an AIDS population from the Midwest of Brazil<\/div><div class = \"text-block\">Identify socio-demographic factors potentially associated with CrAg+;<\/div><div class = \"text-block\">Identify clinical and laboratory aspects potentially associated with the CrAg+<\/div><div class = \"text-block\">To evaluate the percentage of cryptococcal meningitis among patients with CrAg+<\/div><div class = \"text-block\">To mesure outcomes of CrAg+ and CrAg- subjects<\/div><\/div>"}}],"cases":null,"data":null,"section":null,"section_color":null,"critical":null,"critical_id":null,"duration":0},{"id":743789,"guid":"9CA7EB7E94254F889602DCC80B1E77E4","previous_id":743788,"previous_guid":"B7DF03C01F4E4D3296B2B458E68F2C98","modified_on":0,"protocol_id":0,"components":[{"id":1054723,"guid":"111ED6090EE44AEE8CB5609005B91D25","order_id":1,"type_id":6,"title":"Section","source":{"title":""}},{"id":1054724,"guid":"B2930A5435B54E998B98D477757ED470","order_id":1,"type_id":1,"title":"description","source":{"description":"<div class = \"text-blocks\"><div class = \"text-block\"><span style = \"font-weight:bold;\">Outcomes<\/span><span> -<\/span><span style = \"font-weight:bold;\"> Primary<\/span><\/div><div class = \"text-block\">Retention in care before\/after CRAG screening implementation <\/div><div class = \"text-block\">Adherence to ART<\/div><div class = \"text-block\">Resistance to current ARV<\/div><div class = \"text-block\">Time to undetectable viral load after recruitment<\/div><div class = \"text-block\">Adherence to treatment (pre-emptive fluconazole or amphotericin regime)<\/div><\/div>"}}],"cases":null,"data":null,"section":null,"section_color":null,"critical":null,"critical_id":null,"duration":0},{"id":743790,"guid":"F0E48DC141C44D9C9060DBAF693974A5","previous_id":743789,"previous_guid":"9CA7EB7E94254F889602DCC80B1E77E4","modified_on":0,"protocol_id":0,"components":[{"id":1054723,"guid":"140E5960F7F94F518DFBDF58349DCFF4","order_id":1,"type_id":6,"title":"Section","source":{"title":""}},{"id":1054724,"guid":"EC0B3115CC054B7F93F490911EAFBA90","order_id":1,"type_id":1,"title":"description","source":{"description":"<div class = \"text-blocks\"><div class = \"text-block\"><span style = \"font-weight:bold;\">Outcomes - Secondary<\/span><\/div><div class = \"text-block\">Survival time among CRAG+ vs. CRAG negative persons with CD4<200 cells\nCryptococcal meningitis-free survival time in those who are CRAG positive and treated regularly or irregularly with fluconazole compared to CRAG-negative persons with CD4<200\nCryptococcal meningitis survival time\nAll-cause discontinuation of fluconazole\nOpportunistic diseases during follow up\nCause of death<\/div><\/div>"}}],"cases":null,"data":null,"section":null,"section_color":null,"critical":null,"critical_id":null,"duration":0},{"id":743791,"guid":"9D70F3187B76491E94C1B06980E40D56","previous_id":743787,"previous_guid":"6137B3EF574C4DF88959801581222ECE","modified_on":0,"protocol_id":0,"components":[{"id":1054723,"guid":"14CC5A0533214A35A789909DD30C8D1A","order_id":1,"type_id":6,"title":"Section","source":{"title":""}},{"id":1054724,"guid":"B0732288EC114557A32D3B6E9D5E62FB","order_id":1,"type_id":1,"title":"description","source":{"description":"<div class = \"text-blocks\"><div class = \"text-block\">The follow-up will be maintained according to service routine.  <\/div><div class = \"text-block\">Chart review (physical and electronic medical records) will access  outcomes at the end of recruitment period, in 6 and 12 months for follow-up evaluation.<\/div><\/div>"}}],"cases":null,"data":null,"section":null,"section_color":null,"critical":null,"critical_id":null,"duration":0},{"id":743795,"guid":"3ACC44C07B0111E9821BADCEB9CA6790","previous_id":743779,"previous_guid":"ADBFE864E4464B899D66CB6A7CC83E88","modified_on":0,"protocol_id":0,"components":[{"id":1054723,"guid":"D93435B2C7E5481292879BE0262FB7C3","order_id":1,"type_id":6,"title":"Section","source":{"title":""}},{"id":1054724,"guid":"BE8E47532D6C49C99662FD56D995906C","order_id":1,"type_id":1,"title":"description","source":{"description":"<div class = \"text-blocks\"><div class = \"text-block\"><span style = \"font-weight:bold;\">Consent Form <\/span><\/div><div class = \"text-block\">The interviewee will be informed that acceptance or refusal will not interfere with their regular follow-up at the service. After agreeing to participate, the written informed consent will be collected. The individuals allow the use of anonymous data for future scientific publications<\/div><\/div>"}}],"cases":null,"data":null,"section":null,"section_color":null,"critical":null,"critical_id":null,"duration":0}],"materials":[],"description":"<div class = \"text-blocks\"><div class = \"text-block\">This is a study carried out in partnership with of the Brazilian Cryptococcosis Network. It is the implementation of cryptococcal antigen (CRAG) screening and preemptive anti-fungal therapy of HIV-infected persons with advanced immunosuppression (CD4<200 cells\/\u00b5l). <\/div><div class = \"text-block\">It aime to evaluate the prevalence of CrAg antigenemia, its associated factors and to measure outcomes of CrAg positive and negative subjects. <\/div><div class = \"text-block\">The participants will be recruited from June 2015 to July 2018 and followed through December 2019. Outpatients and inpatients assisted at the Tropical Diseases State Hospital \u201cDr. Anuar Auad\u201d, in Goi\u00e2nia, State of Goi\u00e1s, Brazil, will have a serum CRAG performed by lateral flow assay. The population will be composed by adults, with HIV diagnosis, with a CD4 count \u2264200 cells\/\u00b5L, regardless of symptoms and with no history of cryptococcal disease. Lumbar puncture will be performed in every CrAg-positive individual to rule out cryptococcal disease.<\/div><div class = \"text-block\">Those who are CRAG-positive and have no CNS involvement will be treated pre-emptively with high dose fluconazole. Six months and 12 months after the end of recruitment period, the medical records will be reassessed for information of survival with retention-in-care in CRAG positive and CRAG negative and comparisons between groups.<\/div><\/div>","changed_on":1564157162}